A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 1b Study to Evaluate the Safety, Efficacy and Mircobiological Response of Oral ABI-M201 in Subjects With Mildly-to-Moderately Active UC With Ongoing Mesalamine Treatment
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs ABI M201 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Assembly Biosciences
- 27 Jun 2019 According to an Assembly Biosciences media release, first patient has been dosed in the trial.
- 17 Apr 2019 Status changed from planning to recruiting.
- 26 Nov 2018 New trial record